Veracyte reported $79.79M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
Agenus USD 38.52M 3.2M Mar/2026
Agilent USD 281.97M 252K Jun/2026
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 141.14M 564K Jun/2026
Bruker USD 152.35M 130K Jun/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Illumina USD 151.3M 607K Jun/2026
Intrexon USD 0 0 Jun/2024
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
Laboratory Of America USD 80.9M 1.4M Jun/2026
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
Myriad Genetics USD 93.5M 400K Dec/2025
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Roche Holding CHF 796.77M 1.15M Jun/2026
Siemens EUR 762.74M 0 Jun/2026
Sonic Healthcare AUD 4.15B 467K Dec/2024
Thermo Fisher Scientific USD 371.62M 1000 Jun/2026
Veracyte USD 79.79M 1000 Jun/2026
Waters USD 98.19M 20K Jun/2026